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Abstract 
Purpose of review:  The oral glucose tolerance test (OGTT) is used both in clinical practice and research 
to assess glucose tolerance.  In addition, the OGTT is utilized for surrogate measures of insulin sensitivity 
and the insulin response to enteral glucose, and has been widely applied in the evaluation of β-cell 
dysfunction in obesity, prediabetes, and type 2 diabetes.  Here we review the use of the OGTT and the 
OGTT-derived indices for measurement of risk markers for type 2 diabetes in youth.    
Recent findings:  Advantages of using the OGTT for measures of diabetes risk include its accessibility 
and the incorporation of physiological contributions of the gut-pancreas axis in the measures of insulin 
response to glucose.  Mathematical modeling expands the potential gains from the OGTT in physiology 
and clinical research.  Disadvantages include individual differences in the rate of glucose absorption that 
modify insulin responses, imperfect control of the glycemic stimulus, and poor intraindividual 
reproducibility.   
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Summary:  Available research suggests the OGTT provides valuable information about the development 
of impaired glycemic control and β-cell function in obese youth along the spectrum of glucose tolerance.   
 
Introduction 
Type 2 diabetes (T2D) is a disorder characterized by reduced insulin sensitivity, worsening pancreatic 
islet β-cell function, progressive metabolic dysfunction, and dysglycemia.(1)  Studies in youth have 
shown declining β-cell function along the spectrum of glucose tolerance, with obese youth having poorer 
β-cell function than lean youth, and youth with prediabetes and T2D having progressively deteriorating β-
cell function.(2, 3)  The underlying defects leading to dysglycemia in youth appear to differ from adults, 
which increases the need for research to better understand the pathophysiology and measureable risk 
factors for T2D in youth.(4)   
 
Measuring risk for T2D in clinical research has focused on assessing β-cell function.  Methods for 
measuring human β-cell function range in complexity from fasting laboratory measures to intravenous 
infusions of multiple stimulators of insulin release.(5)  Selection of the optimum approach to assessing β-
cell function includes consideration of the pertinent physiology, and also consideration of cost, resource 
availability, and participant burden (Table 1).   
 
The oral glucose tolerance test (OGTT) is used both in clinical practice and research to assess glucose 
tolerance.(6)  In addition, blood samples from the OGTT can be utilized for surrogate measures of insulin 
sensitivity, the insulin response to enteral glucose, and indices of β-cell function.  Since the OGTT 
employs commonly available laboratory tests and clinical protocols, it is generally accessible for use in 
large-scale clinical and epidemiologic studies and has been widely applied in the evaluation of β-cell 
dysfunction in obesity, prediabetes, and T2D.(7, 8)  Additionally, it is a useful tool for assessing the 
effects of treatment on measures of β-cell function.(9, 10)   
 Here we review the pertinent physiology contributing to T2D, the necessary variables for measurement of 
β-cell function, and the use of the OGTT for measurement of β-cell function.  We discuss common 
indices of insulin sensitivity and β-cell function calculated from OGTT-derived data, limitations of oral 
methods, and the use of modelling to augment interpretation of OGTT data. 
 
Physiological Considerations for Measuring Indices of Risk for T2D 
Under normal physiologic conditions, insulin secretion is stimulated, most notably by glucose, in a 
manner that maintains blood glucose within a normal physiological range.(11, 12)  Intracellular 
mechanisms triggering the fusion of insulin granules to the cellular membrane and insulin release result in 
a biphasic insulin response.(11, 12)  The first-phase insulin response occurs quickly after circulating 
glucose concentrations increase, peaks within a few minutes, and subsides within 10 minutes.(13)  The 
second-phase insulin response begins concurrently and consists of a slow and sustained increase in insulin 
concentrations.(13-15)   
 
The development of T2D is characterized by poor insulin sensitivity (insulin resistance), poor or absent 
first-phase insulin, progressively worsening integrated insulin response, declining β-cell function (poorer 
insulin response adjusted for insulin sensitivity), and progressively worsening dysglycemia.(16)  Insulin 
resistance may be defined as decreased responsiveness to the metabolic actions of insulin, including 
reduction in glucose disposal and the failure to suppress hepatic glucose production.  When insulin 
sensitivity declines, a greater insulin response is needed to maintain normal glucose concentrations.  
Increased islet size and β-cell surface area is evident in pancreas samples from normoglycemic patients 
with insulin resistance who undergo pancreatoduodenectomies, suggesting that insulin resistance alters 
the β-cell even in the nondiabetic state.(17)   
 
Insulin clearance is an important physiological consideration for measuring the insulin response to 
glucose.  Insulin undergoes first-pass metabolism in the liver, where much of the insulin is cleared from 
the blood stream.  Rates of insulin clearance differ among individuals.  Individuals with higher rates of 
insulin clearance have lower circulating insulin concentrations, as compared with individuals with low 
rates of insulin clearance.(18-20)  Thus, peripheral blood samples for insulin concentrations can be an 
inaccurate indicator of the actual pre-hepatic insulin levels and are not representative of actual insulin 
secretion.  C-peptide does not undergo first pass metabolism in the liver; thus, C-peptide concentrations 
are often also measured and serve as a correlate of insulin secretion and the insulin response.(21, 22)  
Circulating insulin levels, however, are appropriately utilized in measures of insulin action.   
 
OGTT Procedures and Measures of Glucose Tolerance 
A principle reason an OGTT is performed for both clinical and research purposes is to assess glucose 
tolerance.  The OGTT is less frequently used for diagnostic purposes in the non-pregnant state since 
glycated hemoglobin (Hb A1c) has been endorsed for screening and diagnosis.(6, 23, 24)  Currently, 
clinical guidelines for youth who should have an OGTT for screening purposes include: patients with 
cystic fibrosis, annually, starting at age 10 years (25, 26); and pregnant females (27).  In the absence of 
these conditions, there are no clinical guidelines recommending routine OGTT testing for screening 
purposes in obese youth.  A standard (1.75 g/kg body weight, up to 75 g) OGTT is a minimal risk 
procedure that is applicable for large-scale screening in research protocols, or clinical diagnosis when 
there is continued weight gain and suspicion of progression of dysglycemia in patients with HbA1c in the 
prediabetes range.(23)  In cases where there is continued weight gain, no clinical improvement, and rising 
HbA1c in the prediabetes range, using an OGTT to potentially make an earlier diagnosis of T2D may be 
beneficial, as youth are at risk for complications of diabetes, including diabetic ketoacidosis.(28) The 2-hr 
OGTT should be performed after a 10-12 hour overnight fast. A peripheral intravenous line may be 
inserted and maintained for frequent blood sampling.  For clinical purposes, baseline fasting and 2-hr post 
ingestion blood samples are obtained for measurement of plasma glucose concentrations.   
 For research purposes, additional blood samples are obtained, and insulin and C-peptide measures, as well 
as other pertinent hormones, are measured simultaneously.(29)  Two (or more) baseline samples are 
obtained (commonly at -15 and 0 minutes) for measurements of plasma glucose and insulin/C-peptide. 
Insulin is secreted in a pulsatile and oscillatory pattern, thus taking the average of multiple (at least two) 
baseline measures is recommended.(11, 12)   Thereafter, the flavored glucose is given orally and blood 
samples are obtained as necessary for the given protocol (commonly +15, 30, 60, 90, and 120 minutes). 
More frequently sampling during the initial 30 minutes of the test and/or an extended duration of testing 
may be desired, particularly if mathematical modeling will be utilized to derive indices of insulin 
response to glucose.(30)   
 
OGTT-derived standards for the diagnosis of T2D, as well as impaired fasting glucose and impaired 
glucose tolerance are identical for adults and youth.(6)   In the non-pregnant state, normal fasting plasma 
glucose is <100 mg/dL (6.11 mM).  Fasting glucose levels between 100 and 125 mg/dL indicate impaired 
fasting glucose. Fasting glucose levels ≥126 mg/dL are consistent with diabetes. Two elevated readings 
on 2 separate days are needed to make a diagnosis. A random plasma glucose ≥200 mg/dL is consistent 
with diabetes if the individual has symptoms such as polyuria and polydipsia. During an OGTT (in the 
non-pregnant state), a 2-hour plasma glucose value of <140 mg/dL is considered normal, ≥140 and <200 
mg/dL is considered impaired glucose tolerance, and ≥200 mg/dL is considered diabetes. 
 
While the diagnosis of prediabetes (either impaired fasting glucose, or impaired glucose tolerance, or 
both) is useful for broad diagnostic categorization and implies increased risk for T2D, there are 
pathophysiologic differences, with some overlap, in the two conditions.(3, 31)  Youth with either isolated 
impaired fasting glucose or impaired glucose tolerance have both 1) reduced first-phase and second-phase 
insulin responses to intravenous glucose and 2) greater endogenous glucose production due to hepatic 
resistance to the action of insulin.(31)  However, youth with isolated impaired fasting glucose appear to 
have superior peripheral insulin sensitivity compared with youth with impaired glucose tolerance.3,25  
Youth with the combination of impaired fasting glucose and impaired glucose tolerance have more 
substantial reductions in first- and second-phase insulin responses, and worse β-cell function, similar to 
youth with T2D.(3, 32) 
 
An additional point of consideration is poor reproducibility of OGTT data, especially in individuals at 
risk for T2D.(8, 29, 33)  In a study of 60 obese youth who underwent two separate OGTTs within 25 
days, the percent positive agreement between the first and second OGTT was low for impaired fasting 
glucose (22%) and impaired glucose tolerance (27%).(29)  Those who had discordant OGTT results had 
lower insulin response relative to insulin sensitivity, suggesting that variability on OGTT may be 
indicative of a higher risk of developing diabetes.   
 
Measures of Insulin Sensitivity from the Oral Glucose Tolerance Test  
The OGTT does not allow for direct measures of insulin sensitivity, but does allow for both fasting and 
glucose-stimulated surrogate measures of insulin sensitivity.  As insulin sensitivity decreases, despite the 
increase in insulin concentrations, there is inadequate suppression of hepatic glucose output and fasting 
glucose concentrations increase.  Decreased rates of glucose disposal associated with reduced peripheral 
(muscle and adipose tissue) insulin action are associated with greater glycemic excursions (per unit of 
insulin) during the OGTT.(7, 34)  Indices of insulin sensitivity have been developed using both fasting 
and stimulated blood samples:  inverse fasting insulin, homeostatic model assessment (HOMA, calculator 
at http://www.dtu.ox.ac.uk)(35), quantitative insulin sensitivity check index which is a permutation of 
HOMA (QUICKI = 1/(logI0 + logG0))(36), and the combined plasma glucose and insulin excursions 
during the OGTT (whole body insulin sensitivity index, WBISI, or Matsuda-Defronzo index = 1000/√ (G0 
I0) * (Gmean Imean)).(37)  The composite WBISI is based on values of insulin (µU/mL) and glucose (mg/dL) 
obtained at baseline and 30 minutes during the OGTT. The WBISI correlated to measures of glucose 
disposal derived from the euglycemic-hyperinsulinemic clamp in youth (r~0.8).(34, 38) Other dynamic 
measures of insulin sensitivity obtained during an OGTT have been described by Stumvoll (39), Belfiore 
(40), and Gutt et al (41). 
 
Of the fasting measures, inverse fasting insulin and HOMA-IS correlate reasonably well with the clamp 
insulin sensitivity index (r= 0.6-0.7).(5, 42)  Irrespective of glucose tolerance status, the simple 
calculation of 1/fasting insulin correlates with clamp-measured insulin sensitivity comparably to HOMA 
or QUICKI.(34)  Thus, the more complicated calculations, as well as OGTT-based surrogate estimates of 
insulin sensitivity, may be unnecessarily costly or cumbersome in cross-sectional, large-scale studies. 
Lower correlations between OGTT-derived indices and clamp insulin sensitivity compared with fasting 
indices may be related to the poor reproducibility of OGTT-derived measures in obese youth.(29)   
 
While surrogate estimates of insulin sensitivity are useful in large-scale epidemiological or treatment 
studies, these measures may not be sensitive enough to detect changes in insulin sensitivity over time in 
longitudinal studies with relatively small number of participants.  Correlations between longitudinal 
changes in surrogate indices of insulin resistance and more direct measures (hyperinsulinemic-euglycemic 
clamp or intravenous glucose tolerance test with minimal model-derived measures of insulin sensitivity) 
have rarely been formally evaluated. Xiang et al. followed a cohort of women with gestational diabetes in 
a longitudinal study and found changes in surrogate indices of insulin sensitivity to be less strongly 
correlated to changes in minimal model-derived measures, as compared to cross-sectional studies.(43)   
Moreover, it is inappropriate to use any surrogate measure of insulin sensitivity as a diagnosis of insulin 
resistance.  There are no cut-points for “insulin sensitive” or “insulin resistant” states, as there is much 




Measures of Insulin Response from the Oral Glucose Tolerance Test  
The OGTT does not allow for direct measures of biphasic (first- and second-phase) insulin response.  
First-phase insulin response is strictly measured in the first 10 minutes after administration of intravenous 
glucose, and not after enteral glucose.(13)  Multiple factors associated with oral but not intravenous 
glucose administration make it impossible to distinguish a first-phase insulin response during the OGTT.  
For example, the appearance of glucose in the circulation is relatively delayed, and gastrointestinal 
absorption and rates of rise in glucose concentrations vary among individuals.  Thus, during the OGTT, 
the insulin responses may be defined as “early” and “late-phase” insulin responses to an oral glucose 
load.(5)  The early-phase insulin response is generally accepted as the rise in insulin (C-peptide) above 
basal levels within 30 minutes of glucose load.(5, 44)  The late-phase insulin response is less frequently 
used or defined, as it overlaps with the early-phase response.  Insulin (C-peptide) area under the curve is 
more frequently utilized.(34, 38, 44)   
 
To adequately sample varying insulin (C-peptide) concentrations frequent blood sampling is required and 
timing of the OGTT may be extended over the standard 2 hours.(30)  In general, a 2-hour OGTT with 
blood samples at baseline (fasting) and 15 (or 10 and 20), 30, 60, 90, and 120 minutes have been most 
commonly used.   Timing of samples during OGTT, however, should pay special attention to the first 30 
minutes, while still accurately representing the glucose curve over the entire duration of the test.  Though 
the first 30 minute period also includes the initial late-phase response, it encompasses the early-phase 
insulin response by definition.  Despite its mixed character, the early-phase insulin response is 
measurably decreased with worsening dysglycemia, similar to first-phase insulin secretion measured by 
hyperglycemic clamp.(7, 45)  
 
The most common OGTT-derived indices of insulin response include the insulinogenic and C-peptide 
indices, both of which express incremental change in insulin and C-peptide levels, respectively, against 
change in glucose levels over the same time period (change in insulin or C-peptide divided by change in 
glucose from 0 to 30 min).(44)  However, there are circumstances where the measured insulin 
concentration at 30 min is lower than the insulin concentration at baseline, producing a negative value for 
the insulinogenic index.(46) This is likely due to measurement variability associated with the insulin 
assay at low concentrations of insulin.  The prevalence of negative values is low overall, but increases in 
individuals with diabetes (~3%).(46)  Worsening glycemic control results in more variability of glucose 
response to enteral stimuli and poorer reproducibility of OGTT results, and declining β-cell function 
makes it technically more difficult to measure insulin response and the measurement variability with the 
insulin assay becomes a dominant feature of the measurement itself .(47)  The precision of glucose 
measures is better in individuals with lower glucose concentrations and measureable insulin response , 
compared with individuals with diminished insulin response .(47)   
 
Total insulin response from the OGTT has been expressed integrated insulin responses as the incremental 
AUC insulin to glucose response, or the integrated insulin response.(48, 49)  Integrated measures have 
been shown to have less variability than indices based on acute insulin responses.(50)  However, 
integrated measures have the disadvantage of being a poorer reflection of the insulin response phase most 
dramatically affected early in the development of dysglycemia. Interpretation of the insulin response 
(either early phase or integrated response) separate without consideration of the prevailing insulin 
sensitivity is fraught with problems of interpretation, as insulin concentrations overlap in those with 
normal and impaired insulin response depending on the degree of insulin resistance and impairment of β-
cell function.   
 
The shape of the glucose response curve, monophasic versus biphasic, during the OGTT can also lend 
insight to physiological factors related to the development of diabetes.(51-55)  A monophasic glucose 
response curve represents a gradual increase in glucose concentrations followed by a subsequent decrease 
in glucose.(52) Whereas a biphasic glucose response curve represents a curve with a second rise in 
glucose concentrations after the decline in glucose has occurred. In youth without diabetes, individuals 
with a monophasic glucose response curve appear to have greater risk factors for T2D, including lower 
clamp-derived hepatic and total body insulin sensitivity, and insulin response relative to insulin sensitivity 
(disposition index).(56)     
 
Expressing β-Cell Function using Measures from the Oral Glucose Tolerance Test 
Measures of β-cell function assess the ability of β cells to generate an effective insulin response to a given 
stimulus, accounting for the prevailing insulin sensitivity.  The mathematical equation for the square 
hyperbolic relationship linking insulin sensitivity and insulin response is commonly expressed as a 
“disposition index” (DI; insulin sensitivity × first-phase insulin response) (Figure 1).(57, 58) The DI is an 
expression of the acute insulin response adjusted for prevailing insulin sensitivity, and is utilized as a 
measure of β-cell function.  A falling DI in an individual represents physiologic decompensation.(59, 60)  
To express a DI, one needs both measures of insulin sensitivity and stimulated insulin response.   
 
Despite some limitations, the OGTT can be used to assess β-cell function. The use of OGTT variables to 
derive a DI (oral DI, oDI) is supported by mathematical evidence for an underlying hyperbolic 
relationship between surrogate measures of insulin sensitivity and insulin response from the OGTT.(8, 
61) OGTT-derived measures of insulin response can be adjusted for insulin sensitivity using a surrogate 
measure, such as fasting insulin concentration or HOMA%S, or using a separate direct measurement.(5)  
Regardless, the oDI generally seems to have at least modest correlations to clamp-derived DI regardless 
of glucose tolerance category in youth(60, 62), is associated with poor glycemic control in youth(32), and 





OGTT more closely reflects the integrated physiologic response to ingested stimuli than clamp or 
intravenous tolerance tests, as it allows assessments of the important physiological potentiating 
contributions of the gut-pancreas axis in the measure of insulin responses.(64)  The incretin effect, 
referring to a higher insulin response to oral glucose than to intravenous glucose even at similar levels of 
glycemia, acknowledges the role of incretins such as glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP) which potentiate the insulin response to an oral glycemic 
stimulus.(65, 66)  While both incretins offer long-term anti-apoptotic or proliferative benefits which are 
beyond the scope of this review, more salient to the OGTT is their effect on glycemic control - both 
incretins enhance insulin response, while GLP-1 also decreases glucagon secretion and enhances β-cell 
glucose sensitivity.(67)  When an OGTT is combined with an intravenous test (IVGTT or hyperglycemic 
clamp), this allows comparisons of responses to enteral versus parenteral stimulation, enabling assessment 
of the contributions of the incretin effect to the insulin response to ingested glucose.(68, 69)   
 
Existing evidence in youth suggests a pattern of poorer incretin effect with worsening glycemic 
control.(70) In a study of 255 obese youth, Michaliszyn et al. found the ratio of OGTT-derived glucose 
sensitivity (β-cell response to glucose) to hyperglycemic clamp-derived glucose sensitivity was 
significantly reduced in youth with impaired glucose tolerance versus those with normal glucose 
tolerance.(69)  The incretin effect was not further diminished in youth with T2D.  When compared to 
youth with normal glucose tolerance, youth with impaired glucose tolerance had 1) no difference in 
incretin concentrations, 2) similar hyperglycemic clamp-derived insulin responses, and 3) lower OGTT-
derived β-cell glucose responsiveness.  These findings suggest that reduced incretin effect originates 
downstream of hormone production, and loss of the incretin effect may precede measurable declines in β-
cell function. Variability in the incretin effect may also contribute to the increased intraindividual 
variability in OGTT results in youth with declining β-cell function. 
 
Mathematical Modeling of OGTT-derived Data to Assess β-Cell Function 
The adaptation of mathematical minimal model methodologies for use with enteral stimuli has further 
extended our ability to utilize multiple-sample OGTT results.(71-73)  Rather than relying on direct 
measurements of insulin sensitivity and insulin secretion, modeling employs mathematical descriptions of 
expected physiological behavior – glucose response to insulin and β-cell insulin (C-peptide) response to 
glucose – that are fitted to individual OGTT patient data.  Modeling also provides the opportunity to 
mathematically investigate incretin augmentation of insulin secretion.(69, 73)  
 
Currently, two main models have been proposed and are frequently referenced.  Both models separate β-
cell responsivity into two distinct components –a response based on absolute glucose level (static 
secretion), and a response based on the rate of change of glucose (dynamic secretion).  Mari, Ferrannini 
and colleagues have introduced a methodology wherein glucose data is first interpolated, then used with 
insulin or C-peptide data to describe the dependence of insulin response on glucose concentration.(73)  
Individual participant data is fitted to adjust parameter outputs.  The authors have employed a 
‘potentiation factor’ as necessary in creating an appropriate dose-response fit, and propose that this factor 
encompasses multiple factors affecting insulin response, including incretins.  Cobelli and colleagues have 
introduced a methodology based on two simultaneous models.(71, 72)  The glucose model describes the 
modulating effect of insulin on glucose disappearance from the oral load, while a C-peptide based model 
describes β-cell responsivity to glucose.  This model postulates approximate physiological parallels, 
suggesting that dynamic insulin secretion is likely reflective of immediate insulin release, while static 
insulin secretion is likely related to insulin granule mobilization, thus correlating to early- and late-phase 
insulin secretion.(72)  Similar models were originally formulated for use with intravenous glucose 
tolerance tests, but have since been adapted for use with OGTTs and mixed meal tests.(72, 74)  They have 
been validated for reduced sampling schedules, and been shown to be a valuable tool in the adolescent 
population.(4, 45, 71, 72)    
 
The use of mathematical modeling to augment findings based on OGTT has several advantages.  It allows 
multiple parameters (insulin action and insulin (C-peptide) response) to be derived while forgoing multi-
day testing.  The distinction of dynamic and static insulin secretion allows for approximate localization of 
β-cell failure, with clinically meaningful correlates.(72)  Moreover, the measured parameters and their 
DIs may offer better discrimination of changes along the spectrum of glycemic control, compared to 
calculated indices from the first 30 minutes of the OGTT.(4)    
 
Conclusions 
The OGTT is relatively simple, widely accessible, and incorporates the physiological contributions of the 
gut–pancreas axis in the measure of β-cell responses.  Disadvantages of OGTT methodology for 
measuring β-cell function include differences in the rate of glucose absorption that can modify the 
observed response, imperfect control of the glycemic stimulus to insulin secretion, and higher 
intraindividual variability in glucose tolerance and measures of β-cell function compared with that seen 
with intravenous testing.  Nevertheless, available research suggests that it provides valuable information 
about the development of impaired glycemic control, and those factors which create more variability can 
themselves be examined for greater insight into the pathophysiology of diabetes.  Mathematical modeling 
is applicable to OGTT-derived data, thus expanding the potential gains from the OGTT in physiology and 
clinical research.   
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Figure 1. The hyperbolic relationship between insulin secretion and insulin sensitivity. Lean, insulin-
sensitive individuals require lower levels of insulinemia; obese, insulin-resistant but normoglycemic 
individuals compensate with an increased insulin response to glucose. Impaired glucose tolerance 
develops when the insulin response is insufficient to overcome insulin resistance, and the disposition 
index (DI), which is β-cell function relative to insulin sensitivity (insulin secretion × insulin sensitivity), 
declines.  (From: Hannon and Arslanian, Annals of the New York Academy of Sciences. 2015;1353:113-
37, modified and used with permission) [2]. 
 
